Cyclic phosphatidic acid influences the expression and regulation of cyclic nucleotide phosphodiesterase 3B and lipolysis in 3T3-L1 cells

Biochemical and Biophysical Research Communications

Volumn 404, Issue 1, 2011, Pages 109-114

  Tsukahara, Tamotsu ^a   Hanazawa, Shuwa ^b   Murakami Murofushi, Kimiko ^b  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OCHANOMIZU UNIVERSITY   (Japan)

Author keywords

Adipogenesis; Cyclic phosphatidic acid; Lipolysis; Lysophospholipids; Phosphodiesterase; PPAR

Indexed keywords

ANTILIPEMIC AGENT; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 3B; CYCLIC PHOSPHATIDIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ARTICLE; CELL FUNCTION; CELL LEVEL; CELL STRAIN 3T3; CELL STRAIN 3T3 L1; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION REGULATION; LIPID STORAGE; LIPOLYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ANIMALS; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; HETEROCYCLIC COMPOUNDS, 1-RING; LIPOLYSIS; MICE; PHOSPHATIDIC ACIDS; PPAR GAMMA;

EID: 78650863340     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.11.076     Document Type: Article

References (34)

1. WHO, Global Strategy on Diet, Physical Activity and Health, 2009.
2. Tontonoz P., Hu E., Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994, 79:1147-1156.
3. Evans M., Park Y., Pariza M., Curtis L., Kuebler B., McIntosh M. Trans-10,cis-12 conjugated linoleic acid reduces triglyceride content while differentially affecting peroxisome proliferator activated receptor gamma2 and aP2 expression in 3T3-L1 preadipocytes. Lipids 2001, 36:1223-1232.
4. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., Evans R.M. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995, 83:803-812.
5. McIntyre T.M., Pontsler A.V., Silva A.R., St Hilaire A., Xu Y., Hinshaw J.C., Zimmerman G.A., Hama K., Aoki J., Arai H., Prestwich G.D. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc. Natl. Acad. Sci. USA 2003, 100:131-136.
6. Tsukahara T., Tsukahara R., Yasuda S., Makarova N., Valentine W.J., Allison P., Yuan H., Baker D.L., Li Z., Bittman R., Parrill A., Tigyi G. Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 2006, 281:3398-3407.
7. Davies S.S., Pontsler A.V., Marathe G.K., Harrison K.A., Murphy R.C., Hinshaw J.C., Prestwich G.D., Hilaire A.S., Prescott S.M., Zimmerman G.A., McIntyre T.M. Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists. J. Biol. Chem. 2001, 276:16015-16023.
8. Li Y., Zhang J., Schopfer F.J., Martynowski D., Garcia-Barrio M.T., Kovach A., Suino-Powell K., Baker P.R., Freeman B.A., Chen Y.E., Xu H.E. Molecular recognition of nitrated fatty acids by PPAR gamma. Nat. Struct. Mol. Biol. 2008, 15:865-867.
9. Petersen K.F., Krssak M., Inzucchi S., Cline G.W., Dufour S., Shulman G.I. Mechanism of troglitazone action in type 2 diabetes. Diabetes 2000, 49:827-831.
10. Greene D.A. Rosiglitazone: a new therapy for Type 2 diabetes. Expert. Opin. Investig. Drugs 1999, 8:1709-1719.
11. Boden G., Homko C., Mozzoli M., Showe L.C., Nichols C., Cheung P. Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes 2005, 54:880-885.
12. Zhang C., Baker D.L., Yasuda S., Makarova N., Balazs L., Johnson L.R., Marathe G.K., McIntyre T.M., Xu Y., Prestwich G.D., Byun H.S., Bittman R., Tigyi G. Lysophosphatidic acid induces neointima formation through PPARgamma activation. J. Exp. Med. 2004, 199:763-774.
13. Siess W., Tigyi G. Thrombogenic and atherogenic activities of lysophosphatidic acid. J. Cell. Biochem. 2004, 92:1086-1094.
14. Cheng Y., Makarova N., Tsukahara R., Guo H., Shuyu E., Farrar P., Balazs L., Zhang C., Tigyi G. Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR. Cell. Signal. 2009, 21:1874-1884.
15. Qureshi A.I., Feldmann E., Gomez C.R., Johnston S.C., Kasner S.E., Quick D.C., Rasmussen P.A., Suri M.F., Taylor R.A., Zaidat O.O. Intracranial atherosclerotic disease: an update. Ann. Neurol. 2009, 66:730-738.
16. Wright H.M., Clish C.B., Mikami T., Hauser S., Yanagi K., Hiramatsu R., Serhan C.N., Spiegelman B.M. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J. Biol. Chem. 2000, 275:1873-1877.
17. Lee G., Elwood F., McNally J., Weiszmann J., Lindstrom M., Amaral K., Nakamura M., Miao S., Cao P., Learned R.M., Chen J.L., Li Y. T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J. Biol. Chem. 2002, 277:19649-19657.
18. Tsukahara T., Tsukahara R., Fujiwara Y., Yue J., Cheng Y., Bolen A.L., Zhang C., Balazs L., Re F., Du G., Frohman M.A., Baker D.L., Parrill A., Uchiyama A., Tetsuyuki K., Murofushi K., Tigyi G. Phospholipase D2-dependent inhibition of the nuclear hormone receptor PPARγ by cyclic phosphatidic acid. Mol. Cell 2010, 39:421-432.
19. Tsukahara T., Hanazawa S., Kobayashi T., Iwamoto Y., Murakami-Murofushi K. Cyclic phosphatidic acid decreases proliferation and survival of colon cancer cells by inhibiting peroxisome proliferator-activated receptor gamma. Prostaglandins Other Lipid Mediat. 2010, 93:126-133.
20. Tigyi G. Aiming drug discovery at lysophosphatidic acid targets. Br. J. Pharmacol. 2010, 161:241-270.
21. Murakami-Murofushi K., Shioda M., Kaji K., Yoshida S., Murofushi H. Inhibition of eukaryotic DNA polymerase alpha with a novel lysophosphatidic acid (PHYLPA) isolated from myxoamoebae of Physarum polycephalum. J. Biol. Chem. 1992, 267:21512-21517.
22. Murakami-Murofushi K., Uchiyama A., Fujiwara Y., Kobayashi T., Kobayashi S., Mukai M., Murofushi H., Tigyi G. Biological functions of a novel lipid mediator, cyclic phosphatidic acid. Biochim. Biophys. Acta 2002, 1582:1-7.
23. Murakami-Murofushi K., Mukai M., Kobayashi S., Kobayashi T., Tigyi G., Murofushi H. A novel lipid mediator, cyclic phosphatidic acid (cPA), and its biological functions. Ann. NY Acad. Sci. 2000, 905:319-321.
24. Friedman P., Haimovitz R., Markman O., Roberts M.F., Shinitzky M. Conversion of lysophospholipids to cyclic lysophosphatidic acid by phospholipase D. J. Biol. Chem. 1996, 271:953-957.
25. Rahn Landstrom T., Mei J., Karlsson M., Manganiello V., Degerman E. Down-regulation of cyclic-nucleotide phosphodiesterase 3B in 3T3-L1 adipocytes induced by tumour necrosis factor alpha and cAMP. Biochem. J. 2000, 346 Pt 2:337-343.
26. Degerman E., Landstrom T.R., Wijkander J., Holst L.S., Ahmad F., Belfrage P., Manganiello V. Phosphorylation and activation of hormone-sensitive adipocyte phosphodiesterase type 3B. Methods 1998, 14:43-53.
27. Guo L., Li Q., Wang W., Yu P., Pan H., Li P., Sun Y., Zhang J. Apelin inhibits insulin secretion in pancreatic beta-cells by activation of PI3-kinase-phosphodiesterase 3B. Endocr. Res. 2009, 34:142-154.
28. Nagaoka T., Shirakawa T., Balon T.W., Russell J.C., Fujita-Yamaguchi Y. Cyclic nucleotide phosphodiesterase 3 expression in vivo: evidence for tissue-specific expression of phosphodiesterase 3A or 3B mRNA and activity in the aorta and adipose tissue of atherosclerosis-prone insulin-resistant rats. Diabetes 1998, 47:1135-1144.
29. Uchiyama A., Mukai M., Fujiwara Y., Kobayashi S., Kawai N., Murofushi H., Inoue M., Enoki S., Tanaka Y., Niki T., Kobayashi T., Tigyi G., Murakami-Murofushi K. Inhibition of transcellular tumor cell migration and metastasis by novel carba-derivatives of cyclic phosphatidic acid. Biochim. Biophys. Acta 2007, 1771:103-112.
30. Gerhold D.L., Liu F., Jiang G., Li Z., Xu J., Lu M., Sachs J.R., Bagchi A., Fridman A., Holder D.J., Doebber T.W., Berger J., Elbrecht A., Moller D.E., Zhang B.B. Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists. Endocrinology 2002, 143:2106-2118.
31. Omori K., Kotera J. Overview of PDEs and their regulation. Circ. Res. 2007, 100:309-327.
32. Degerman E., Belfrage P., Newman A.H., Rice K.C., Manganiello V.C. Purification of the putative hormone-sensitive cyclic AMP phosphodiesterase from rat adipose tissue using a derivative of cilostamide as a novel affinity ligand. J. Biol. Chem. 1987, 262:5797-5807.
33. Mukai M., Imamura F., Ayaki M., Shinkai K., Iwasaki T., Murakami-Murofushi K., Murofushi H., Kobayashi S., Yamamoto T., Nakamura H., Akedo H. Inhibition of tumor invasion and metastasis by a novel lysophosphatidic acid (cyclic LPA). Int. J. Cancer 1999, 81:918-922.
34. Mukai M., Nakamura H., Tatsuta M., Iwasaki T., Togawa A., Imamura F., Akedo H. Hepatoma cell migration through a mesothelial cell monolayer is inhibited by cyclic AMP-elevating agents via a Rho-dependent pathway. FEBS Lett. 2000, 484:69-73.